10x Genomics (TXG) Total Non-Current Liabilities (2018 - 2026)

10x Genomics has reported Total Non-Current Liabilities for 9 years, with the latest figure at $195.0 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 2.05% year-over-year to $195.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $195.0 million (up 2.05% YoY) and the FY2025 annual result came in at $238.6 million, up 14.42% from the prior year.
• Total Non-Current Liabilities eased to $195.0 million in Q1 2026 per TXG's latest filing, from $238.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $238.6 million in Q4 2025 and troughed at $188.0 million in Q1 2022.
• A 5-year average of $207.0 million and a median of $204.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities increased 18.01% in 2022, then dropped 10.02% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $220.3 million in 2022, then declined by 0.2% to $219.8 million in 2023, then slipped by 5.15% to $208.5 million in 2024, then increased by 14.42% to $238.6 million in 2025, then dropped by 18.26% to $195.0 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $195.0 million, $238.6 million, and $235.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.